Catalyst Prescribed drugs, Inc. (NASDAQ:CPRX) Q3 2024 Earnings Convention Name November 7, 2024 8:30 AM ET
Firm Contributors
Richard Daly – President and Chief Government Officer
Michael Kalb – Chief Monetary Officer
Jeffrey Del Carmen – Chief Industrial Officer
Steven Miller – Chief Working Officer and Chief Scientific Officer
Gary Ingenito – Chief Medical & Regulatory Officer
Convention Name Contributors
Joon Lee – Truist Securities
Charles Duncan – Cantor Fitzgerald
Samantha Semenkow – Citi Funding Analysis
Operator
Thanks for standing by. My title is Kris and I shall be your convention operator at present. At the moment, I want to welcome everybody to the Catalyst Prescribed drugs’ Third Quarter 2024 Monetary Outcomes Convention Name. [Operator Instructions] Thanks.
I might now like to show the decision over to Mike Kalb, CFO. Please go forward.
Michael Kalb
Thanks. Good morning, everybody, and thanks for becoming a member of our convention name to debate Catalyst Prescribed drugs’ third quarter 2024 monetary outcomes and enterprise highlights. Wealthy Daly, President and CEO will lead the decision at present; and Jeffrey Del Carmen, our Chief Industrial Officer, and I may also current. Moreover, Dr. Steve Miller, our Chief Working Officer and Chief Scientific Officer shall be accessible for the Q&A.
Earlier than we start, I want to remind you that in our remarks this morning and within the Q&A session, we’ll make statements about anticipated future outcomes, which can be forward-looking statements for functions of federal securities legal guidelines. These statements relate to our present expectations, estimates, and projections, and are usually not ensures of future efficiency. They contain dangers, uncertainties, and assumptions which can be tough to foretell and should not show to be correct. Precise outcomes could differ from the expectations contained in our forward-looking statements.
These forward-looking statements ought to be thought-about solely along with the detailed data
